Eagle Pharmaceuticals Inc (NASDAQ:EGRX) – Analysts at Cantor Fitzgerald issued their FY2020 earnings per share estimates for Eagle Pharmaceuticals in a note issued to investors on Wednesday, November 13th. Cantor Fitzgerald analyst B. Folkes forecasts that the specialty pharmaceutical company will post earnings per share of $2.03 for the year.
Other research analysts have also issued reports about the stock. BidaskClub lowered shares of Eagle Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Thursday, November 7th. ValuEngine lowered shares of Eagle Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, October 19th. Zacks Investment Research lowered shares of Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a research note on Thursday, October 17th. Royal Bank of Canada reiterated a “buy” rating and issued a $66.00 price objective on shares of Eagle Pharmaceuticals in a report on Sunday, August 11th. Finally, TheStreet upgraded shares of Eagle Pharmaceuticals from a “c+” rating to a “b-” rating in a report on Thursday, September 19th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company. Eagle Pharmaceuticals has an average rating of “Hold” and a consensus price target of $60.25.
Shares of Eagle Pharmaceuticals stock opened at $56.83 on Monday. The firm has a market capitalization of $776.66 million, a PE ratio of 27.19 and a beta of 1.43. Eagle Pharmaceuticals has a twelve month low of $36.03 and a twelve month high of $64.94. The firm’s 50-day moving average price is $60.80 and its 200 day moving average price is $56.50. The company has a current ratio of 4.24, a quick ratio of 3.36 and a debt-to-equity ratio of 0.20.
Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its quarterly earnings results on Tuesday, November 12th. The specialty pharmaceutical company reported $0.26 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.43 by ($0.17). The company had revenue of $41.10 million during the quarter, compared to analysts’ expectations of $45.44 million. Eagle Pharmaceuticals had a net margin of 12.72% and a return on equity of 16.07%. The company’s quarterly revenue was down 19.9% compared to the same quarter last year. During the same period in the prior year, the business posted $1.18 earnings per share.
In other Eagle Pharmaceuticals news, Director Hudson Executive Capital Lp sold 15,437 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $63.57, for a total value of $981,330.09. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. In the last quarter, insiders sold 51,179 shares of company stock valued at $3,184,071. 31.70% of the stock is owned by insiders.
A number of hedge funds have recently added to or reduced their stakes in EGRX. Cubist Systematic Strategies LLC increased its holdings in shares of Eagle Pharmaceuticals by 2.5% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 8,677 shares of the specialty pharmaceutical company’s stock worth $483,000 after buying an additional 214 shares during the last quarter. US Bancorp DE increased its holdings in shares of Eagle Pharmaceuticals by 5.4% during the 2nd quarter. US Bancorp DE now owns 8,269 shares of the specialty pharmaceutical company’s stock worth $460,000 after buying an additional 427 shares during the last quarter. Strs Ohio increased its holdings in shares of Eagle Pharmaceuticals by 4.2% during the 2nd quarter. Strs Ohio now owns 12,400 shares of the specialty pharmaceutical company’s stock worth $690,000 after buying an additional 500 shares during the last quarter. Northern Trust Corp increased its holdings in shares of Eagle Pharmaceuticals by 0.4% during the 2nd quarter. Northern Trust Corp now owns 145,597 shares of the specialty pharmaceutical company’s stock worth $8,106,000 after buying an additional 529 shares during the last quarter. Finally, State of Tennessee Treasury Department increased its holdings in shares of Eagle Pharmaceuticals by 7.3% during the 3rd quarter. State of Tennessee Treasury Department now owns 8,098 shares of the specialty pharmaceutical company’s stock worth $458,000 after buying an additional 552 shares during the last quarter. Institutional investors own 99.56% of the company’s stock.
Eagle Pharmaceuticals Company Profile
Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers Argatroban, an anti-coagulant thrombin inhibitor for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL); and Belrapzo, a chemotherapeutic agent for CLL and Indolent NHL.
Further Reading: How is the LIBOR rate calculated?
Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.